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Abstract Reprogramming of somatic cells into inducible
pluripotent stem cells (iPSCs) provides an alternative to
using embryonic stem cells (ESCs). Mesenchymal stem
cells derived from human hair follicles (hHF-MSCs) are
easily accessible, reproducible by direct plucking of human
hairs. Whether these hHF-MSCs can be reprogrammed has
not been previously reported. Here we report the generation
of iPSCs from hHF-MSCs obtained by plucking several
hairs. hHF-MSCs were isolated from hair follicle tissues
and their mesenchymal nature confirmed by detecting cell
surface antigens and multilineage differentiation potential
towards adipocytes and osteoblasts. They were then reprog-
rammed into iPSCs by lentiviral transduction with Oct4,
Sox2, c-Myc and Klf4. hHF-MSC-derived iPSCs appeared
indistinguishable from human embryonic stem cells
(hESCs) in colony morphology, expression of alkaline phos-
photase, and expression of specific hESCs surface markers,
SSEA-3, SSEA-4, Tra-1-60, Tra-1-81, Nanog, Oct4, E-
Cadherin and endogenous pluripotent genes. When injected
into immunocompromised mice, hHF-MSC-derived iPSCs
formed teratomas containing representatives of all three
germ layers. This is the first study to report reprogramming
of hHF-MSCs into iPSCs.
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Abbreviations
iPSCs Induced pluripotent stem cells
ESCs Embryonic stem cells
hESCs Human embryonic stem cells
MSCs Mesenchymal stem cells
hHF-MSCs Human hair follicle mesenchymal stem cells
MEFs Mouse embryonic fibroblasts
Introduction
A major goal of stem cell research is the use of cells
obtained from patient-derived pluripotent cells for therapeu-
tic purposes. Embryonic stem cells (ESCs) are the most
primitive stem cells. They are derived from pre-
implantation embryos, and can differentiate into all three
embryonic germ layers [1]. The characterization of ESCs as
totipotent has made them a powerful tool for regenerative
medicine. However, hESC-based therapeutic research is
technically challenging and further complicated by ethical
and legal concerns, significantly limiting its potential.
Therefore, it has been the goal of the scientific community
to explore new and innovative approaches to obtain hESC-
like cells that do not destroy human embryos[2, 3].
Recently, iPSCs have been generated from both mouse
and human fibroblasts following ectopic expression of the
two transcription factors Oct4 and Sox2, combined with
either c-Myc and Klf4 or Lin28 and Nanog [2–5]. These
cells share many characteristics with ESCs, including the
potential for pluripotent differentiation and capability for
intensive proliferation in vitro. This result has not only
facilitated disease research but also lays an important foun-
dation for producing autologous cell therapies. Following
this breakthrough, a variety of cells from mice, humans and
other species have been used in reprogramming experi-
ments, including fibroblasts[2–7], pancreatic β cells [8],
hepatocytes [9], hematopoietic cells [10, 11], neural stem
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cells [12, 13], and mesenchymal stem cells (MSCs) [14–16].
MSCs derived from different tissues demonstrated various
reactions to the Yamanaka factors (Oct4, Sox2, c-Myc,
Klf4) but were not easier to reprogram because they are
relatively primitive compared with other differentiated cells.
Simply using Yamanaka factors failed to induce MSCs from
human bone marrow to produce cells with ESC-like prop-
erties. The addition of human telomerase to catalyze subunit
hTERT and SV40 large T-Antigen was also required to
reprogram these MSCs [14]. Reprogramming mouse and
human adipose tissue-derived MSCs into iPSCs has a
higher efficiency compared with that for mouse and hu-
man fibroblasts [15]. MSCs or progenitor cells derived
from teeth or dental pulp can also be reprogrammed into
iPSCs [16]. Nevertheless, similar problems were encoun-
tered when attempting to reprogram these cells, for exam-
ple: limited sources, difficulty in obtaining them, and the
reality that the sampling procedure itself may cause injury
to the individual donor.The ideal target somatic cells
should be safely and easily accessible, methods for their
retrieval reproducible, and the harvesting procedure rela-
tively noninvasive.
Hair follicles are renewable organs, they undergo repeat-
ed cycles of growth (anagen), regression (catagen), and rest
(telogen) throughout the life of mammals [17].
It has been reported that there is an essential role for
the follicular dermal papilla and its related dermal sheath
cells in hair follicle development and regeneration [18].
At present, the majority of skin biology research is
focused on epidermal stem cells. However, the character-
istics of MSCs also can be observed in hair follicle
dermal cells [19, 20]. Our study first confirmed the
existence of hair follicle derived MSCs obtained by di-
rect plucking of human hairs. This method eliminates
many problems associated with other procedures, and
the resulting MSCs were found to be multipotent with
potential to be directed toward differentiation into adipo-
cytes and osteoblasts.
In this study, we sought to determine whether hHF-MSCs
represent a cell type that may be reprogrammed to generate
iPSCs. If so, this would provide a new source of reprogram-




After the approval of the study protocol by the Ethics
committee of Jilin Province (China) and written informed
consent, hHF-MSCs were obtained from the scalp of one of
the authors by plucking the hairs.
Cell Culture
Several hairs with a full hair follicle were plucked, the root
tissue cut with sterile ophthalmic scissors, and then placed
into phosphate-buffered saline (PBS) containing penicillin
and streptomycin. Hair follicle root tissues were rinsed three
times in PBS containing penicillin and streptomycin, then
placed into 96-well plates, cultured with hHF-MSCs medi-
um: Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s
F-12 medium (DMEM/F12; Invitrogen, Carlsbad, CA,
USA), 10 % fetal bovine serum (FBS; Hyclone, Victoria,
Australia), 2 ng/ml basic fibroblast growth factor (bFGF;
Invitrogen). Cells were passaged once the plate surface was
covered with confluent cells. hHF-MSCs were frozen and
stored in liquid nitrogen at passages 0–2. Cells were thawed
and expanded for experimentation at passages 2–3. CF-1
mouse embryonic fibroblasts (MEFs) used in this report
were derived from an embryonic day 12.5 embryo pool of
CF-I mice. MEFs were cultured in DMEM (Invitrogen)
supplemented with 10 % FBS. hESCs (X01) [21], obtained
from the Xiaolei Group (Shanghai Institute of Biochemistry
and Cell Biology, Shanghai Institutes for Biological Sci-
ence, Chinese Academy of Sciences), and hHF-MSC-
derived iPSCs were maintained in irradiated CF-1 MEFs
in hESCs culture medium (80 % DMEM/F12 supplemented
with 20 % KnockOut serum replacement, 1 % non-essential
amino acids, 1 mML-glutamine, 4 ng/ml human bFGF,
0.1 mM β-mercaptoethanol (all from Invitrogen). The
hHF-MSC-derived iPSCs and hESCs were split with
1 mg/ml collagenase type IV (Invitrogen) for about 30 min
at 37 °C, at a ratio of 1:6 every 6–7 days. Conditioned
medium was collected according to Xu et al. [22].
Immunophenotyping of hHF-MSCs
Immunophenotyping was carried out as described previously
[23]. Antibodies used were anti-CD29, anti-CD45, anti-
CD105, anti-HLA-DR (Biolegend, USA), anti-CD90, anti-
CD31, anti-CD73 (BD, USA) and anti-CD15 (Abcam, MA).
Differentiation Experiments
Adipogenic differentiation and detection was performed as
previously described [23]. Osteogenic differentiation was in-
duced by culturing cells at 80–90 % confluency in low glu-
cose DMEM containing 10 % FBS, 10−8 μMdexamethasone,
10 mM β-glycerophosphate (Sigma-Aldrich, USA), and
0.2 mML-ascorbic acid (Sigma-Aldrich, USA) for 3–4 weeks.
Mediumwas replaced every 3 days.Mineralized bone nodules
were detected using Alizarin Red S and Alkaline Phosphatase
staining. Positive Alizarin Red S staining indicated calcium
deposition, while Alkaline Phosphatase staining was black for
bone nodules.
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Lentivirus Production and Establishment of hHF-MSC-
Derived iPSCs
We followed the protocol for lentiviral transduction as previ-
ously described [24]. Briefly, 3.6 μg of lentivirus vector, pLV-
EF1α-CDNA-IRES-EGFP, was designed to carry one of the
four transcription factor sequences encodingOct4, Sox2, c-Myc
or Klf4. 2.7 μg of lentiviral vector pCMVΔ8.91 and 1.8 μg of
vesicular stomatitis virus G protein (VSV-G) were co-
transfected into Human embryonic kidney (HEK) 293T cells
(obtained from the Xiaolei Group, Shanghai Institute of Bio-
chemistry and Cell Biology, Shanghai Institutes for Biological
Science, Chinese Academy of Sciences) in T25 flask with
Fugene HD transfection reagent (Roche, USA), respectively.
Viral supernatants at 48 or 72 h post-transfection were collected
for determination of viral titer. hHF-MSCs were transduced
with a cocktail of lentiviruses carrying reprogramming factors
at Day 0. At 24 h post-transduction, cells were harvested by
trypsinization and plated ontoMEFs (5 × 104 cells per well) in a
six-well plate. The next day, medium was replaced with hESCs
culture medium. On Day 25, iPS colonies were picked and
plated onto new culture dishes.
Immunostaining
Immunostaining was carried out as previously described [25].
The primary antibodies used were: monoclonal anti-SSEA3
(1:200 dilution; Developmental Studies Hybridoma Bank);
monoclonal anti-SSEA4 (1:400; Developmental Studies Hy-
bridoma Bank); anti-Tra-1-60 (1:150; Chemicon, USA); anti-
Tra-1-81 (1:150; Chemicon, USA); anti-Nanog (1:150; R&D
Systems, USA); anti-Oct4 (1:100; Santa Cruz Biotechnology,
Santa Cruz, CA, USA); and anti-E-Cadherin (1:100; Becton
Dickinson, USA).
RNA Isolation and Quantitative Real-Time Polymerase
Chain Reaction (qPCR)
Total RNAwas extracted with TRIZOL reagent (Invitrogen)
and used as a template for reverse transcription. The qPCR
assays were performed in a Bio-Rad iQ5 real-time PCR
detection system (Bio-Rad, Hercules, CA, USA) using a
SYBR Green PCR Master mix (TOBOYO). The PCR pri-
mers are listed in Supplemental Table S1. Each assay was
carried out in triplicate. Standard curves were acquired for
both the gene of interest and the internal control,
glyceraldehyde-3-phsosphate dehydrogenase (GAPDH).
The CT data for the gene of interest and GAPDH were
obtained from the qPCR assays then transformed into copy
numbers using the standard curve. The expression value of
each gene was normalized to the amount of GAPDH cDNA
to calculate the relative amount of RNA present in each
sample. The mRNA copy number of the gene of interest
was defined as the number of copies per 106 copies of
GAPDH.
Karyotype Analysis
Karyotyping was performed at the Xiangtan Center Hospital
using standard protocols for high-resolution G-banding.
Teratoma Formation
The hHF-MSC-derived iPSCswere injected intramuscularly into
non-obese diabetic/severe combined immune deficient (NOD/
SCID) mice (approximately 5×106 cells per site). Two hHF-
MSC-derived iPSC lines at a passage greater than 10 were used
to produce teratomas. Threemice were injected for each cell line.
Three tumors were generated when hHF-MSC-derived iPSCs
10-1 was used. Two tumors were generated when hHF-MSC-
derived iPSCs 20-1 was used, (10-1 and 20-1 means the gener-
ated iPSCs as the multiplicity of infection of 10 or 20). After
8 weeks, tumors were processed for hematoxylin-eosin staining.
DNA Fingerprinting Analysis
To confirm the hHF-MSCs origins of the hHF-MSC-derived
iPSCs, short tandem repeat (STR) analysis was performed by
Beijing Microread Gene Technology Co., Ltd. (Beijing, China).
Results
Isolation and Characterization of hHF-MSCs
The hHF-MSCs migrated outwards from the human hair
follicle root tissue and adhered to the surface of the culture
plate (Fig. 1a, b). They were passaged every 3–4 days to a
maximum of 12 passages without major morphological
alteration. The primary and passaged cells all displayed
typical fibroblast-like morphology (Fig. 1d, e, f). The hair
follicle is a complex organ, and it is one of the few organs of
the body that undergoes cyclic bouts of degeneration and
regeneration throughout life [26]. It contains a variety of
different types of cells. In the primary culture, in addition to
hHF-MSCs, keratinocytes were also observed around the
hair follicle (Fig. 1c), as described previously by Aasen et
al. [27].
Flow cytometry (2×105 cells were used for each anti-
body) demonstrated that the majority of the hHF-MSCs
expressed the MSC markers CD29, CD73, CD105, CD90
(99.8 %, 98.4 %, 84.4 % and 99.5 %, respectively). In
contrast, hematopoietic (CD31, CD45) and keratinocyte
(CK15) markers were not detected. Additionally, cell pop-
ulations were negative for the major histocompatibility com-
plex (MHC) class II (HLA-DR) antigen (Fig. 1g).
Stem Cell Rev and Rep (2013) 9:451–460 453
The hHF-MSCs had multilineage differentiation poten-
tial. After adipogenic induction for 4–5 days, the morphol-
ogy of the cells changed from long spindle-shape into a
round or polygonal shape. One week later, small bubble-
shaped lipid droplets appeared in part of the cells (Supple-
mental Figure S1). After induction for 3 weeks, both the size
and the number of lipid droplets were all increased, and
most of the differentiated cells showed red lipid droplets
throughout their cytoplasm (Fig. 1i, j).
When hHF-MSCs were cultured in osteogenic medi-
um for 4 weeks, osteoblast-like cells were clearly dem-
onstrated by alkaline phosphatase staining (Fig. 1m). In
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vitro mineralization could be shown by Alizarin red
staining (Fig. 1l).
Formation of hESCs-Like Colonies and Their Expansion
The schematic diagram of the reprogramming protocol is
shown in Fig. 2a, and detailed methods are included in the
“Materials and Methods” section. Viruses expressing a
cocktail of reprogramming factors (OCT4, SOX2, C-MYC
and KLF4) were used to transduce hHF-MSCs. 24 h after
transduction, the cells were harvested by trypsinization and
plated onto MEFs. Colonies with a hESCs-like morphology
first became visible 7 days after transduction. When the
colonies had been grown for 25–30 days, 131 colonies were
picked mechanically according to the morphological char-
acteristics of hESCs. Two hESCs-like colonies were finally
selected on the basis of further characterization, and were
named, hHF-MSC-derived iPSCs 10-1 and hHF-MSC-
derived iPSCs 20-1 (Fig. 2b).
hHF-MSC-Derived iPSCs Exhibit Similar Morphology
and Marker Expression to hESCs
hHF-MSC-derived iPSCs exhibited a similar morphology to
that of hESCs, characterized by a high nucleus to cytoplasm
ratio and prominent nucleoli. They have now been passaged
continuously for more than 20 passages (>120 days). As
observed in hESCs, the hHF-MSC-derived iPSCs expressed
typical hESCs surface markers, including stage-specific em-
bryonic antigen SSEA-3, SSEA-4, TRA-1-60, TRA-1-81
and E-Cadherin. They have also expressed alkaline phos-
phatase, Nanog (Fig. 3).
We used quantitative PCR to analyze the expression of
endogenous Oct4 and Sox2 and other pluripotency-
associated genes, including Nanog, Cripto, FoxD3, Lin28,
FGF4 and ESG1. Our results show that all of these genes
were robustly induced. The expression of endogenous genes
associated with pluripotency in hHF-MSC-derived iPSCs was
effectively raised to a level similar to that observed in hESCs
(Fig. 4a). These observations suggest that endogenous plurip-
otent genes can be fully induced by the reprogramming of
hHF-MSCs. We used absolute quantitative PCR to calculate
the mRNA copy number of Oct4 and Sox2 in these cells and
found that the expression of exogenous genes Oct4 and Sox2
in hHF-MSC-derived iPSCs was downregulated compared to
that in hESCs (Fig. 4b). Karyotype analysis showed that hHF-
MSCs at passage 5, along with hHF-MSC-derived iPSCs 10-1
at passage 10 and hHF-MSC-derived iPSCs 20-1 at passage
11 had a normal male chromosome type (46XY) with no
observable chromosome abnormalities (Fig. 5). DNA finger-
printing analysis confirmed the origin of the reprogrammed
colonies. (Supplemental Table S2).
Teratoma Formation
hHF-MSC-derived iPSCs were injected intramuscularly into
NOD/SCID mice. At 4–5 weeks after injection we observed
tumor formation. After 8 weeks, tumors had formed in three
mice injected with passage 13 hHF-MSC-derived iPSCs 10-
1. Tumors also formed in two mice injected with passage 14
hHF-MSC-derived iPSCs 20-1, one of which died. Histo-
logical examination revealed that the tumors contained var-
ious tissues of the three germ layers, including pigmented
epithelium (ectoderm), neural tissues (ectoderm), cartilage
(mesoderm), gut-like epithelial tissues (endoderm) and res-
piratory epithelium (endoderm) (Fig. 6). Tumors were not
observed in mice injected with hHF-MSCs only.
Discussion
It is possible to use a terminally differentiated somatic cell in
order to produce a whole animal or individual via transfer of
the cell nucleus or cloning [28, 29]. Cell nucleus transfer
technology has shown that differentiated cells can return to
their more immature state if provided with the appropriate
conditions. Recently, somatic cells have been reprogrammed
directly to a pluripotent state by forced expression of four or
less transcription factors to generate personalized iPSCs
[2–16]. This approach not only bypasses immune rejection
but also circumvents barriers of technical, ethical and legal
issues which apply to the use of embryonic materials.
At present, a wide variety of cells from many different
species, including humans, have been reprogrammed into
iPSCs [2–16]. However, the methods for obtaining target cells
for reprogramming are invasive and painful, often accompa-
nied by restrictions on time, place and quantity of available
Fig. 1 Isolation and characterization of human hair follicle mesenchy-
mal stem cells (hHF-MSCs). The hHF-MSCs, resembling typical
fibroblast-like cells, migrated out from the hair follicles (a Bars0
500 μm; b Bars0100 μm). Keratinocytes also migrated out from the
hair follicles (c Bars0500 μm). hHF-MSCs from passage 2 (d), pas-
sage 8 (e) to passage 12 (F Bars0200 μm). Flow cytometric analysis of
cell surface markers on hHF-derived fibroblast-like cells. 2 × 105 cells
were incubated with primary antibodies against CD29, CD73, CD105,
CD90, HLA-DR, CD31, CK15 or CD45,respectively, followed by
incubation with a secondary FITC-labeled antibody. Controls were
incubated with secondary antibody only. Percentages indicate the frac-
tion of cells that stained positive (g). Adipogenic differentiation of
hHF-MSCs. Compared to non-induced control (h Bars0100 μm),
induction after 3 weeks, the number of intracellular lipid droplets
was further increased (i Bars0100 μm) and was detected by Oil-red
O staining (j Bars0100 μm). Osteogenic differentiation of hHF-MSCs.
Compared to non-induced control (k Bars0200 μm), calcium nodules
were formed after induction for 4 weeks and was demonstrated by
Alizarin red staining (l Bars0200 μm) and Alkaline phosphatase
staining (m Bars0200 μm)

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tissues. In our study we attempted to establish a simple, uni-
versally applicable (any age, sex and physical condition) and
noninvasive sampling method. We also sought to determine
whether hHF-MSCs represent a reprogrammable cell type for
use in generating iPSCs. This is the first report to demonstrate
that hHF-MSCs can be reprogrammed into iPSCs.
Multipotent MSCs were originally found in the bone
marrow, and were considered to be the inherent stem cells
at this location [30]. Later, these MSCs or MSC-like cells
have been separated from, and identified in various tissues,
including white adipose tissue, pancreas, skin, and the um-
bilical cord blood [31–34]. In recent years, studies have
shown the presence of MSCs in the dermal sheath and
dermal papillae of the hair follicle: In 2006, a comparative
study investigated the properties of follicular dermal stem
cells from whisker hairs of Wistar rats and bone marrow
MSCs were isolated from femora of the same animals [35].
The results from that study showed that dermal stem cells
from hair follicles have a similar morphology and popula-
tion doubling time, and express the same cell-surface
markers as the MSCs. Following exposure to appropriate
induction stimuli, both cell populations have the capacity to
differentiate into various mesenchymal lineages, such as
osteoblasts, adipocytes, chondrocytes and myocytes.
Our research group tried to determine whether MSCs can
be obtained from human follicles through plucking meth-
ods. Research on hair follicle stem cells indicates that most
hair follicle samples have been derived from animal back-
skins, or the human scalp by surgical means. If we could
obtain MSCs through simple plucking, it would have great
Fig. 2 Generation of induced pluripotent stem cells from hHF-MSCs.
(a) Schematic diagram of the reprogramming protocol used. (b) hHF-
MSCs were transduced with four factors and seeded onto mouse
embryonic fibroblasts until hESCs-like colonies emerged (representa-
tive colonies). (a) Typical non-hESCs-like colony. (b) hESCs colony,
X01 at passage 24. (c) High magnification of the hESCs at passage 24.
(d) Typical iPS colony, hHF-MSC-derived iPSCs 10-1 at passage 2. (e)
High magnification of the hHF-MSC-derived iPSCs 10-1 at passage 2.
(f) hHF-MSC-derived iPSCs 10-1 at passage 16. (g) Arrow indicates
area of differentiation in the center of hHF-MSC-derived iPSCs 10-1 at
passage 16. (h) hHF-MSC-derived iPSCs 20-1 at passage 3. (i) High
magnification of hHF-MSC-derived iPSCs. at passage 3. (j) hHF-
MSC-derived iPSCs 20-1 at passage 17. (k) High magnification of
hHF-MSC-derived iPSCs 20-1 at passage 17. Bars0200 μm
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significance for stem cell research. Recently, it has been
shown that skin keratinocytes can also be obtained by the
same approach and they have already been reprogrammed
into iPSCs [27]. Since the specific location where hHF-
MSCs reside remains unclear [36], we postulate that there
may be a niche in the dermal sheath and/or hair papilla. In
the process of reprogramming hHF-MSCs, we observed iPS
cell colony formation about 26 days after transduction,
resulting in a reprogramming efficiency of ∼0.001 %.
hHF-MSCs possess lower reprogramming efficiencies than
do cells from human hair follicle dermal papilla which have
a reprogramming efficiency of ∼0.02 %, as shown by
Fig. 3 hESCs pluripotency marker expression by these iPSCs. a
hESCs colonies, X01 at passage 25 were fixed and stained with anti-
bodies against hESCs associated pluripotent proteins and examined
under the fluorescence microscopy. b hHF-MSC-derived iPSCs 10-1 at
passage 5. c hHF-MSC-derived iPSCs 20-1 at passage 6. Expressed
proteins appeared red in the fluorescence microscope. Bars0200 μm
Fig. 4 a Quantitative reverse transcription-polymerase chain reaction
(PCR) analyses of endogenous Oct4, Sox2, Nanog and other pluripo-
tency genes expression in hESCs and hHF-MSC-derived iPSCs
relative to parental somatic cell populations. b Quantitative RT-PCR
analyses of exogenous gene Oct4 and Sox2 expression
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Christiano’s research group [37]. We suggest that the possible
reason for this observation is that the endogenous expression
of Sox2 and Nanog in dermal papilla cells is higher than in
hHF-MSCs, which express low levels of endogenous Sox2
and Nanog (Supplemental Figure S2, Fig. 4a). Possibly these
represent different cell populations of hHF-MSCs. Rendl et
al., using only the transcription factors Oct4 or Oct4/Klf4
successfully reprogrammed mouse dermal papilla cells into
iPSCs [38, 39]. This is in contrast to hHF-MSCs, which are
incapable of being reprogrammed using less than four factors
or use Oct4 alone. This is the same observation as made when
reprogramming human hair follicle dermal papilla cells by
Christiano et al. [37]. There are other noninvasive methods
to obtain cells. Pei et al. [40] have successfully derived iPSCs
from exfoliated renal tubular cells present in urine samples.
This maybe a preferred souce for generating iPSCs.
Although we have a relatively better way to obtain cells,
the lentivirus we used for gene delivery will integrate into
the genome anyway, and may cause insertional mutagenesis
risks that could be resolved via usage of a different ap-
proach, such as synthetic mRNA [41] or any of the other
integration-free approaches that are currently being per-
formed in the field.
We conclude that the hHF-MSCs provides an acces-
sible source for making iPSCs, and that hHF-MSC-
derived iPSCs are morphological similar to hESCs in
that they exhibit a high nuclear/cytoplasmic ratio and
express specific surface markers of hESCs. They also
expressed pluripotency-associated transcription factor
genes at similar levels as hESCs. They were able to
form teratomas in vivo containing tissues of all three
germ layers.
Fig. 5 Karyotype analysis. hHF-MSCs at passage 5 (a), hHF-MSC-derived iPSCs 10-1 at passage 10 (b) and hHF-MSC-derived iPSCs 20-1 at
passage 11(c) all showed a normal 46XY karyotype
Fig. 6 Hematoxylin-eosin staining of teratomas derived from hHF-
MSC-derived iPSCs. Teratomas is composed of various type of tissues:
(a) Pigmented epithelium (ectoderm). b Rosettes of the neural
epithelium (ectoderm). c squamous epithelium (ectoderm). d cartilage
tissue (mesoderm). e Respiratory epithelium (endoderm). f Gland-like
structures (endoderm). Bars0500 μm
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Conclusion
In summary, MSCs were isolated from human hair follicle
tissues by noninvasive means. The differentiation potential
of hHF-MSCs was increased by reprogramming with Yama-
naka factors. The method used to access hHF-MSCs was
very convenient and enabled quick establishment of a large-
scale hHF-MSCs library, which was then used to create an
hHF-MSC-derived iPSCs bank. This work lays the founda-
tion for further research into how these hHF-MSC-derived
iPSCs can be applied to personalized regenerative medicine.
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